Picture of Evolus logo

EOLS — Evolus News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousMid CapNeutral

Evolus Inc expected to post a loss of 5 cents a share - Earnings Preview

* Evolus Inc  EOLS.OQ   EOLS.O  is expected to show a rise
in
quarterly revenue when it reports  results on July 31 for the
period ending June 30 2024
    * The Newport Beach California-based  company is expected to
report a 33.3% increase in revenue to $65.785 million from
$49.35 million a year ago, according to the mean estimate from 6
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Evolus Inc is for a loss
of 5
cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 8 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Evolus Inc
is
$23.00​, above​ its last closing price of $12.31. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Mar. 31 2024  -0.11       -0.10      -0.09     Beat    14.3
 Dec. 31 2024  -0.07       -0.07      -0.12     Missed  -79.1
 Sep. 30 2023  -0.18       -0.17      -0.16     Beat    8​
 Jun. 30 2023  -0.22       -0.19      -0.19     Met     2.3
 ​​Mar.        -0.16       -0.15      -0.15     Met     -1.1
 31 2023                                                
 Dec. 31 2022  -0.13       -0.15      -0.14     Beat    5.3​
 Sep. 30 2022  -0.31       -0.28      -0.28     Met     -1.1
 Jun. 30 2022  -0.25       -0.24      -0.28     Missed  -15.4
 This summary was machine generated July 29 at 21:10 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)

Recent news on Evolus

See all news